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Abstract 
 
Polo-like kinase 1, PLK1, has important functions in maintaining 
genome stability and is involved in regulation of mitosis. PLK1 is up 
regulated in many invasive carcinomas. We asked whether it may also 
play a role in acquisition of invasiveness, a crucial step in transition to 
malignancy. In a model of metaplastic basal-like breast carcinoma 
progression, we found that PLK1 expression is necessary but not 
sufficient to induce invasiveness through laminin-rich extracellular 
matrix. PLK1 mediates invasion via Vimentin and β1 integrin, both of 
which are necessary. We observed that PLK1 phosphorylates Vimentin 
on serine 82, which in turn regulates cell surface levels of β1 integrin. 
We found PLK1 to be also highly expressed in pre-invasive in situ 
carcinomas of the breast. These results support a role for the  
involvement of PLK1 in the invasion process and point to this athway as 
a potential therapeutic target for pre-invasive and invasive breast 
carcinoma treatment. 
 
 
Introduction 
 
PLK1, is a member of the well-conserved family of polo-like kinases 
which has four known members in humans, PLK1,2,3,4. Silencing of 
PLK1 via siRNA induces apoptosis, interferes with mitosis (1, 2), 
inhibits centrosome amplification (3), and down regulates response to 
DNA damage via BRCA2 phosphorylation (1). PLK1 mRNA level is 
transiently down regulated in response to DNA damage and this is 
dependent on BRCA1 and its downstream effectors, CHEK1 kinases (4). 
In addition to DNA damage and mitosis, PLK1 has been implicated in 
the golgi checkpoint pathway that ensures proper segregation of this 
organelle during cell division (5). 
 
Consistent with its known functions, PLK1 expression is regulated 
during cell cycle progression: levels are low in G0, G1, and S, but begin 
to increase in G2 and peak in M phase (reviewed in (6)). PLK1 is 
degraded via an APC dependent proteolysis pathway as cells exit 
mitosis. Interestingly, PLK1 phosphorylates APC, which in turn targets 
PLK1 for degradation. PLK1 levels are also regulated by a direct 
interaction with the chaperone heat shock protein Hsp90, which has 
recently been linked to regulation of MMP function (7, 8). Serum 
induces PLK1 mRNA levels in multiple human cell lines. In general, 
active proliferation has been correlated with high PLK1 levels, and 
differentiation (induced by factors in culture) with low levels, while 
DNA damage acts as a transient down regulator. In normal tissues, 
PLK1 is found only in actively proliferating tissues such as placenta and 
its expression increases in many invasive carcinomas, including breast, 
ovarian, esophageal, head and neck, melanoma tumor specimens.  
 
Using the HMT-3522 cell line series, comprised of the non-invasive S1 
and S2, pre-invasive S3-A,-B,-C, and invasive T4-2 constituting a 
faithful model for the metaplastic basal-like breast cancer sub-type (9-
11), here we found a role for PLK1 in invasion, described a mechanism, 
and propose a therapeutic strategy. 
 
 
Materials and Methods 
 
Cell culture. Cells were grown in tissue culture monolayers (2D) using 
FalconTM  tissue culture plastic or 3DlrECM (MatrigelTM, BD 
Biosciences) in defined medium as described previously (Petersen et al., 
1992; Weaver et al., 1997). S2 and S3 cells were grown under the same 
conditions as T4-2. 
 
RT-PCR. Semi-quantitative RT-PCR for PLK1 was performed using 
the following primers: forward; aggctctgctcggatcga, reverse; 
tctctttcgccggtggag, and conditions (after having determined linear 
range): 96oC 3min, 34x(96oC 30sec, 58oC 30sec, 72oC 1min), 72oC 
5min.  
 
Western blots. SDS-PAGE based standard methods were used. Primary 
antibodies used were: PLK1 rabbit polyclonal to peptide 8-21, 
PC382(Chemicon), 1:200 dilution; vimentin, rabbit polyclonal, JM3634 
(MBL international), 1:100 dilution; phospho vimentin (ser82) D095-3 
(MBL International), 1:500 dilution. 
 
Invasion assay. Invasion through lrECM (Matrigel) was measured in 
Boyden chamber assays, essentially as described (12). The number of 
invading cells (out of 1 X 105 seeded) was determined after 48 hrs of 
incubation (unless indicated otherwise) in either regular growth medium, 
in medium containing different concentrations the GSK compound, or of 
β1 function blocking antibody A2BII (Sierra Biosource), or medium 
containing 2-day conditioned medium from T4-2 cell cultures (for S3-C 
induction). For siRNA treated T4-2 or S3-C cells, transfection of 30-
150nM oligo with siPORT NeoFX (Ambion) was performed 1 day after 
plating cells. After 2 days in culture, siRNA treated cells were 
trypsinized and seeded for Boyden chamber assays. siRNA oligos 
against PLK1 (3’ Alexa 488 labeled from Qiagen, DNA target sequence: 
cgacttcgtgttcgtggtg, described in (1)), VIM (oligo1: Ambion ID 138993; 
oligo 2: Ambion ID 138994; oligo 3: Ambion ID 138995), or scrambled 
control siRNA (Ambion, SilencerTM-Cy3 labeled) were used. 
 
Synchronization. T4-2 cells were kept in DMEM/F12 for 6 hrs for 
synchronization, after 2 days of siRNA inhibition by PLK1 or scrambled 
control. Cells were then plated over a thin layer of lrECM in chamber 
slides, in parallel to plating cells on a similar layer of lrECM for Boyden 
chamber invasion assays. Ki67 positive % was evaluated at 3, 6, 12, 24, 
and 48hrs after release into optimal growth medium, using DAPI 
staining to count total nuclei. A minimum of 200 nuclei from three fields 
were counted for each sample. 
 
Cell surface expression. Live cells were immunostained in suspension 
prior to fixing with 2% paraformaldehyde. Primary antibodies were used 
at 1:10 dilution, and secondary antibodies at 1:100 dilution. FACS 
analysis was performed using EPICS XL-MCL data acquisition and 
display software on XL flow cytometry analyzers (UC Berkeley, Flow 
Cytometry Facility). Gating of FLS vs. LS allowed examination of intact 
cells only, FITC fluorescence peak was evaluated for its median value 
and was corrected using samples that had not been treated with primary 
antibody. Primary antibodies were: β1 integrin, MAB1959 (Chemicon); 
activated β1 integrin, HUTS-21 (BD Pharmigen); 
 
Tumorigenicity. We injected 2 million cells into the left and right 
fourth inguinal mammary glands of female balb/c athymic nude mice 
(Simonsen laboratories). To determine the effect of PLK1 
downregulation on tumorigenicity, PLK1 or scrambled control siRNAs 
were transfected into cells at 90-100% efficiency, cultured for 4 days, 
injected into the fat pad, and allowed to form tumors for 5 weeks 
(minimum time needed for all T4-2 to form tumors).  
 
Immunohistochemistry. Formalin fixed, paraffin embedded human 
breast tissue sections were obtained from the University of California at 
San Francisco, Breast SPORE, tissue core, as 5 µm thick serial sections. 
The cases contained histologically normal, DCIS, and IDC areas on the 
same section, as reported by the case pathologist and found in the 
archive records. H&E sections were examined (by the UCSF tissue core 
staff) to confirm. The paraffin was removed by incubation in Xylene and 
graded alcohols. Tissues were blocked in 3% hydrogen peroxide in PBS. 
Antigen retrieval was performed by incubating in 0.01% pre-warmed 
trypsin in PBS, followed by microwaving in 10mM sodium citrate 
buffer. Tissues were blocked in 1.5% normal horse serum in PBS and 
incubated with 10µg/ml of PLK1 antibody (Calbiochem, Anti-Plk1, 
Human (Rabbit), PC382). Slides were washed with PBS and incubated 
with biotinylated anti-rabbit antibody (1:200 dilution, Vector 
Laboratories, Biotinylated anti-mouse IgG / anti-rabbit IgG (H+L), BA-
1400), followed by streptavidin-HRP (Vector Laboratories, Vectastain 
ABC kit, Elite PK-6100) , and complete DAB (3,3’-Diaminobenzidine 
tetrahydrochloride, SIGMA) medium. Slides were washed and 
counterstained with hematoxylin, followed by dehydration in graded 
alcohols and Xylene. Signal intensity in each cell was scored using a 
Zeiss Axioskop, on a scale of 0 to 3. A minimum of 100 cells were 
counted for all existing distinct normal, DCIS and IDC areas for each 
case.  
 
 
Results 
 
To determine whether there was a correlation between PLK1 expression 
levels and acquisition of invasiveness in the HMT-3522 metaplastic 
breast carcinoma model (Figure 1A), we examined PLK1 mRNA and 
protein levels in these cells, grown either in 2D or 3DlrECM cultures 
(figure 1B). Expression levels varied in S1, S2, S3-A, and S3-B cells 
and did not correlate directly with invasion, suggesting that PLK1 
expression per se is not sufficient for invasion. Consistent with this, over 
expression of PLK1 in S3-C cells had dominant negative effects on 
growth, as had also been previously observed (13), and was not 
sufficient to induce invasiveness (data not shown). To determine if 
PLK1 is necessary for invasion, we down regulated PLK1 levels in T4-2 
and induced S3-C cells using siRNA (1), and found that this 
significantly decreased invasion (Figure 1C). We also found that a 
chemical inhibitor of PLK1 from GlaxoSmithKlein (GSK) induced a 
dose-dependent inhibition of invasion, confirming the siRNA results 
(data  not shown for proprietary reasons dictated by GSK).  
 
To explore the relationship between the effect of PLK1 on growth and 
invasion, we synchronized cells prior to plating on lrECM in the 
chamber, determining both the proportion of cycling cells and the 
number of invading cells at 6, 12, 24 and 48 hrs (Figure 1D). Ki67 
staining at 3 hrs after release from synchronization showed that almost 
complete growth arrest was maintained for both PLK1 and control 
siRNA treated T4-2 cells. At 6 and 12 hrs, there was no significant 
difference in Ki67 positivity but the number of invading cells was 
significantly lower in the PLK1 siRNA-treated cells compared to 
control. The observation that the number of invading cells is down 
regulated before the number of cycling cells is affected by PLK1 siRNA 
treatment allowed us to separate the effect of PLK1 on invasion from its 
effects on growth. In addition, using the proprietary GSK inhibitor of 
PLK1 in T4-2 cells, we saw a reduction in invasion using two low 
concentrations that did not affect growth (data not shown for proprietary 
reasons dictated by GSK). 
 
Based on reports that PLK1 phosphorylates vimentin (VIM) on ser82 
(14), and phosphorylation of vimentin by PKCε on N-terminal serines 
(ser4,6,7,8,9 tested in combination) is important for retargeting of 
endocytosed β1 integrin to the cell surface in mouse embryonic 
fibroblasts (15), we postulated and tested the hypothesis that PLK1 
could function in cell invasiveness by phosphorylating vimentin on 
serine 82 thereby affecting β1 integrin-mediated invasion through 
lrECM (Figure 2A). siRNA inhibition of vimentin down regulated 
invasion (Figure 2B); β1 integrin was expressed at a higher level on the 
surface of T4-2 cells than in S1, S2, and S3s, and its inhibition resulted 
in a decrease of invasiveness in a dose dependent manner (Figure 2C). 
Effects of downregulating PLK1, vimentin, and β1 integrin function 
were not additive or synergistic in any combination (Figure 2D) 
suggesting that the three proteins function in the same invasion pathway. 
Knocking down PLK1 down regulated the level of ser82 phosphorylated 
vimentin (Figure 3A), as well as decreasing the cell surface levels of β1 
integrin (Figure 3C), as did knocking down vimentin (Figure 3C). 
Expressing mutant vimentin which contained a non-phosphorylatable 
ser82 down regulated invasion compared to the wildtype vimentin 
control which had a higher level of phosphorylated ser82 (Figure 3B), as 
well as decreasing the total and activated β1 integrin levels on the cell 
surface (Figure 3D).  
 
To explore the relevance of this PLK1-mediated invasion mechanism to 
tumor phenotypes in vivo, we found that downregulating PLK1 
decreased the tumorigenicity of T4-2 cells in the mouse mammary fat 
pad (Figure 4A).To ask if PLK1 inhibition could potentially be used in 
treatment of pre-invasive breast disease, as well as malignant lesions in 
human breast cancer which had previously been reported to express high 
levels of PLK1 protein, we determined if in situ carcinomas expressed it, 
after confirming the published findings (6) that there was no detectable 
expression in normal tissues and that the invasive tumors displayed high 
immunohistochemical signal: normal = 0.28 +/- 0.15; invasive = 1.96 +/- 
0.06 (Figure 4B,D). In the 8 patient-matched biopsies we examined, in 
situ carcinoma lesions had higher levels of expression than invasive 
carcinoma regions on the same section: in situ = 2.64 +/- 0.84 ; Invasive 
= 1.90 +/- 0.15; p-value = 1.57 x 10-5 (Figure 4C,D). 
 
 
Discussion 
PLK1 has been shown to be up regulated in many malignant cancers, 
and is important for maintaining genome stability via its functions in 
mitosis (16). Here, we found that PLK1 is also necessary (but not 
sufficient) in acquisition of invasiveness in vimentin expressing cells via 
regulating cell surface β1 integrin levels (Figure 2-3). Such acquired 
“moonlighting” functions have been attributed to a number of other 
proteins as well (17, 18). It is possible that the normal function of PLK1 
in mediating intermediate filament regulated events in cytokinesis 
manifests itself aberrantly when placed in the context of a malignant 
cell, resulting in a regulatory function for invasion. Although we 
demonstrated a role for PLK1 in invasion via vimentin and β1 integrin, 
recent data for the involvement of the yeast polo-like kinase CDC5 in 
cytokinesis via targeting and activation of RhoA at the cleavage furrow 
(19) suggest that actin filaments could potentially be involved in this 
regulation.  
During mitosis, adherent cells first round up and decrease their 
attachment to the substrate, but after cytokinesis they increase 
attachment and spread. The dynamics of attachment and detachment is 
critical for cells to go through mitosis (20). Consistent with this, we 
found the cell surface levels of β1 integrin to be regulated by PLK1 via 
phosphorylation of vimentin on serine 82 (Figure 3). However, in this 
model, we also found the effects of PLK1 on mitosis and invasion to be 
separable (Figure 2, and GSK compound data). Additional support for 
the separability of mitosis and invasion effects in this pathway comes 
from our observation that vimentin siRNAs which down regulate 
invasion do not have any effects on growth (data not shown).  
In addition to PLK1, another protein involved in maintaining genome 
stability, the double-strand break repair protein Ku80, has been shown to 
be involved in invasion (18). Ku80 interacts with MMP9 on the cell 
surface, and its inhibition results in reduced invasion. PLK1 down 
regulation does not affect MMP9 activity (data not shown), suggesting 
an MMP9 independent function. In addition, we found that the 
centromeric protein CENPA and the double-strand break repair protein 
XRCC3 were involved in invasion in Boyden chamber assays, whereas 
the M2 subunit of ribonucleotide reductase RRM2 was not (data not 
shown).We have now dubbed these genes Genomic Instability and 
Extracellular Matrix Invasion (GISEM) genes. Targeting the acquired or 
“moonlighting” invasion function without disrupting the ability of 
GISEM genes such as PLK1 to maintain a stable genome in normal cells 
could constitute new anti-cancer therapies with reduced toxicity. 
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 Figure legends 
 
Figure 1. PLK1 is necessary but not sufficient for invasion 
A. The HMT-3522 model of metaplastic breast cancer progression (9). 
B. RT-PCR analysis for mRNA and Western blot for protein levels of 
PLK1. S1 cells in 2D or 3DlrECM were grown in the absence of EGF in 
order to completely growth arrest cells as a negative control for PLK1 
signal. C. Western blot for PLK1 in cells transfected with siRNA to 
PLK1 vs. Scr.; 44% and 46% reduction in T4-2 and S3-C cells, 
respectively; and invasion assay for T4-2 or S3-C cells (induced by T4-2 
CM), after cells were transfected with PLK1 vs. Scr. siRNA; three 
experiments, duplicate samples. D. %Ki67 positive T4-2 cells 
transfected with PLK1( ) or ( ) Scr. siRNAs, at indicated time points 
after release from synchrony; and invasion assay for theseT4-2 cells. 
 
Figure 2. Vimentin, and β1 integrin are necessary for PLK1-
mediated invasion 
A. The mechanism proposed.  B. Western blot for vimentin in T4-2 cells 
transfected with the indicated siRNAs; Vim2 used for subsequent 
experiments; and invasion assay for T4-2 cells transfected with the 
indicated siRNAs; four experiments, duplicate samples. C. Cell surface 
expression of β1 integrin; four experiments; values normalized to S1; 
p<0.05 between T4-2 and all other cell types; and invasion assay for T4-
2 cells treated with the indicated amounts of β1 integrin blocking 
antibody A2BII; p<0.05 compared to untreated control, six experiments. 
D. Invasion assay for T4-2 cells treated with siRNAs against PLK1 or 
Vimentin, or β1 blocking antibody, in combinations indicated; four 
experiments, duplicate samples; p<0.05 compared to Scr.  
 
Figure 3. PLK1 affects invasion via phosphorylating Vimentin and 
downregulating cell-surface β1 integrin 
A. Western blot for serine 82 phosphorylated vimentin in T4-2 cells 
treated with the indicated siRNAs. B. Western blot for serine 82 
phosphorylated vimentin in T4-2 cells infected with lentivirus 
expressing wildype vimentin pVIM (WT) or mutated vimentin pVIM 
(S82A); and invasion assay for T4-2 samples infected with lentivirus 
expressing a WT vimentin pVIM (WT) or mutated vimentin pVIM 
(S82A); normalized to WT values; p=0.036, three experiments, triplicate 
samples. C. Cell surface expression of β1 integrin on T4-2 cells treated 
with the indicated siRNAs; p-value (PLK1-Scr.) = 0.0007, p-value 
(VIM-Scr.) = 0.003; four experiments. D. Cell surface β1 integrin levels 
(total and active, as indicated), normalized to T4-2 cells expressing WT 
vimentin; four experiments.  
 
Figure 7. PLK1 in vivo 
A. Frequency of tumor formation and mean tumor volumes in fat pad; 
T4-2 transfected with siRNA against PLK1 (n=10) vs. Scr. (n=5). B. 
Control experiment for immunohistochemical detection of PLK1, 
comparing mock antibody to PLK1 antibody treated samples, scale bar 
100µm. C. Example; PLK1 immunohistochemical signal in normal, in 
situ, and invasive samples, from the same patient, scale bar 100µm. D. 
PLK1 signal intensity; 2 normal (N) and 2 invasive (I) cases as controls, 
compared to 8 cases each containing areas of normal (N), as well as in 
situ / pre-invasive (P) and invasive carcinomas (I). 
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